A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
Phase 1/2
180
about 3.4 years
18+
3 sites in CO, FL, NY
What this study is about
Researchers are testing a treatment called STP938 in adults with relapsed or refractory B-cell and T-cell lymphomas. The trial will first determine the best dose of STP938 to use, then expand it to include more patients who are receiving this treatment.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take STP938
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Objective Response Rate (ORR) (Phase 2 / Dose Expansion), Safety and Tolerability (Phase 1 / Dose Escalation)
Secondary: Area under the curve (AUC) of STP938 including effects of food on absorption (Phase 1 / Dose Escalation), Evaluate best overall response of STP938 (Phase 1 / Phase 2), Evaluation Duration of Response (Phase 1 / Phase 2), Evaluation Progression Free Survival (Phase 1 / Phase 2), Evaluation of Complete Response Rate (Phase 2), Maximum plasma concentration (Cmax) of STP938 including effects of food on absorption (Phase 1 / Dose Escalation), Safety and Tolerability (Phase 2 / Dose Expansion), Time to reach maximum concentration (TMax) of STP938 including effects of food on absorption (Phase 1 / Dose Escalation)
Oncology